Advice
In the absence of a submission from the holder of the marketing authorisation.
fondaparinux (Arixtra) is not recommended for use within NHS Scotland for the treatment of acute deep vein thrombosis (DVT) and the treatment of acute pulmonary embolism (PE).
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice29KB (PDF)
Medicine details
- Medicine name:
- fondaparinux (Arixtra)
- SMC ID:
- 262/06
- Indication:
- Acute deep vein thrombosis acute pulmonary embolism
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Cardiovascular system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 08 May 2006